Psychiatric Disorders and Quality of Life in Egyptian Patients with Chronic Immune Thrombocytopenic Purpura: A Single Center Study
- 53 Downloads
The impact of chronic immune thrombocytopenic purpura (ITP) on the psychological health and quality of life is evident among children and adolescents. We aimed to describe psychological disorders and assess quality of life in children with chronic ITP and compared their results with their healthy peers. A cross-sectional comparative study was carried out in a tertiary care university-affiliated hospital during a period from November, 2015 till April, 2018. We enrolled 119 children with chronic ITP and compared with 220 healthy peers. Relevant demographic and clinical data were collected and statistically analyzed. Quality of life for both patients and control groups was measured using pediatric quality of life inventory version 4 (Arabic one). Also psychiatric evaluation of both groups was done using Arabic version of Mini-International Neuropsychiatric Interview for Children (Mini-KID). Majority of patients (90.7%) exhibited mucocutaneous bleeding. Most of patients (61.3%) did not need any definitive treatment for chronic ITP while 38.6% received second line therapy. About one-third of the patients needed rescue medications to control active bleeding. The scores of all sub-scales of Peds QL 4.0 were significantly decreased among patients group when compared to their healthy peers (P < 0.001). General anxiety disorder and oppositional defiant disorders were the commonest psychiatric disorders among children with chronic ITP. Quality of life in children with chronic ITP is markedly impaired with occurrence of a variable spectrum of psychiatric disorders among the studied patients.
KeywordsChildren Psychiatry Quality of life Immune thrombocytopenic purpura
Immune thrombocytopenic purpura
Quality of life
Health-related quality of life
Pediatric quality of life inventory version 4
We greatly acknowledge the patients and their families for their patience and help.
Sohier Yahia: Idea of the research, revising the article draft and final approval of the version to be submitted. Yahya Wahba: Conception and design of the study, collection of clinical data, drafting the article and final approval of the version to be submitted. Abdel-Hady El-Gilany: Analysis and interpretation of data, revising the article draft and final approval of the version to be submitted. Suzy Abdelmabood: Acquisition of hematological data, drafting the article and final approval of the version to be submitted. Mohamed Adel El-Hadidy: Acquisition and analysis of the psychiatric data, revising the article draft and final approval of the version to be submitted. Ahmad Darwish: Analysis of the hematological data, revising the article draft and final approval of the version to be submitted. Ahmed Mansour K: Analysis of the hematological data, conception of the study, drafting the article and final approval of the version to be submitted.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with Ethical Standards
Conflict of interest
Authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 17.Ibrahim M, Bishry Z, Hamed A (2002) Comparison of mini international neuropsychiatric interview for children (MINI-KID) with the schedules for affective disorders and schizophrenia for school aged children, present and lifetime version (KSADS-PL). In: Egyptian sample presenting with childhoo. MD thesis, Ain Shams UniversityGoogle Scholar
- 20.Nazari SH, Abdollah Gorji F, Sadeghi-Koupai MT (2012) Epidemiology of idiopathic thrombocytopenic purpura in children. Iran J Pediatr Hematol Oncol 2:35–39Google Scholar
- 21.Journeycake JM (2012) Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. ASH Educ Progr B 2012:444–449Google Scholar